With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break ...

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options ...

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several months, the companies said.

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with ...

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.

Millions of Medicare patients will be eligible for GLP-1 weight-loss drugs like Ozempic and Wegovy at a cut-rate $50 per ...

CVS Health does a 180. On May 28, CVS Caremark, the pharmacy benefits manager (PBM) under CVS Health's umbrella, announced it ...

Eli Lilly stock jumps on Phase 3 Foundayo (orforglipron) diabetes data beating oral semaglutide—see key trial results, ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

Over 52 weeks, the Achieve-3 study compared two doses of Foundayo with approved oral semaglutide doses in 1,698 people with ...

Foundayo (orforglipron) is a glucagon-like peptide-1 (GLP-1) agonist used for weight management. While Foundayo can be effective, it can interact with other medicines. A drug interaction happens when ...